董梅, 匡铁吉. 临床细菌多重耐药机制研究进展及对策[J]. 解放军医学院学报, 2013, 34(2): 101-103. DOI: 10.3969/j.issn.2095-5227.2013.02.001
引用本文: 董梅, 匡铁吉. 临床细菌多重耐药机制研究进展及对策[J]. 解放军医学院学报, 2013, 34(2): 101-103. DOI: 10.3969/j.issn.2095-5227.2013.02.001
Advances in mechanism of multidrug resistant bacteria and its countermeasure[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2013, 34(2): 101-103. DOI: 10.3969/j.issn.2095-5227.2013.02.001
Citation: Advances in mechanism of multidrug resistant bacteria and its countermeasure[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2013, 34(2): 101-103. DOI: 10.3969/j.issn.2095-5227.2013.02.001

临床细菌多重耐药机制研究进展及对策

Advances in mechanism of multidrug resistant bacteria and its countermeasure

  • 摘要: 临床多重耐药微生物的不断出现和播散,已成为全球关注的公共健康问题,抗菌药物的广泛使用是造成细菌耐药的重要因素之一。多重耐药菌(multidrug resistance bacteria,MDR)是指同时对三类或三类以上抗菌药物产生耐药性的细菌,临床上常见的有超广谱β-内酰胺酶(extended-spectrum β-lactamases,ESBLs)产生菌、耐甲氧西林金黄色葡萄球菌(methicillin-resistant staphylococcus aureus,MRSA)、耐万古霉素的肠球菌(vancomycin resistant enterococci,VRE)、耐碳青霉烯类肠杆菌科细菌(包括NDM-1)、多重耐药结核分枝杆菌(multidrug resistant tuberculosis,MDR-TB)等1。细菌多耐药机制复杂,本文对上述多重耐药菌的耐药机制与应对措施进行了综述。

     

/

返回文章
返回